Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
Healthcare
$1.74 +1.23%
+$0.04 today
- Market cap
- $521.36M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
52W Low $2.58High $6.55
Volume 4.00M
Average 3.76M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$143.83M
FY 2025 · Annual
Investing Cash Flow
-$40.24M
FY 2025 · Annual
Financing Cash Flow
$128.73M
FY 2025 · Annual
-35.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.36M | 38.34M | 35.53M | 37.68M | 25.46M |
| Change in Working Capital | 9.8M | 7.54M | 18.61M | (1.19M) | (10.11M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (266K) | 1.06M | 1.03M | 1.38M | (3.55M) |
| Other Working Capital | 10.07M | 6.48M | 17.58M | (2.56M) | (6.57M) |
| Other Non-Cash Items | 61.64M | (82.08M) | (49.03M) | (10.28M) | 72.24M |
| Operating Cash Flow | (251.05M) | (290.05M) | (253.58M) | (223.15M) | (143.83M) |
| Capital Expenditures | (29.86M) | (20.88M) | (20.03M) | (33.43M) | (938K) |
| Acquisitions (Net) | 0 | (231.44K) | (192.04K) | 0 | 1.43M |
| Purchases of Investments | (491.39M) | (78.69M) | (157.74M) | (226.06M) | (87.29M) |
| Sales of Investments | 280.03M | 310.13M | 349.79M | 276.95M | 46.56M |
| Other Investing Activities | (4.57M) | 231.44K | 192.04K | 17.45M | 0 |
| Investing Cash Flow | (245.8M) | 210.56M | 172.01M | 17.45M | (40.24M) |
| Debt Repayment | 0 | 0 | 0 | 7.74M | (347K) |
| Common Stock Issued | 631.75M | 4.91M | 31.65M | 181M | 129.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 11.01M | 0 |
| Financing Cash Flow | 631.75M | 4.91M | 31.65M | 199.75M | 128.73M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 134.9M | (74.58M) | (49.92M) | (5.95M) | (55.33M) |
| Free Cash Flow | (280.92M) | (310.93M) | (273.61M) | (256.58M) | (144.77M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$244.2M
+ D&A$12.8M
+ Stock-Based Comp$25.5M
+ Deferred Tax$0
- Working Capital-$10.1M
+ Other Non-Cash$72.2M
= Operating Cash Flow-$143.8M
- Capex-$938.0K
= Free Cash Flow-$144.8M
Analysis
FY2025 free cash flow is -$144.8M. FCF conversion is 59.3% of net income. Operating cash flow was -$143.8M, with capex of -$938.0K. The largest bridge item is Other Non-Cash at $72.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 8-K | Current report | Sep 8, 2026 |
Does SANA generate free cash flow?
Sana Biotechnology, Inc. (SANA) generated -$144.77M of free cash flow in fiscal 2025.
How much operating cash flow does SANA produce?
Operating cash flow was -$143.83M, before capital expenditures of $938,000.00.
Continue the stock analysis
Jump to another research area for this company.